Method: LC-MS/MS (Liquid Chromatography/Tandem Mass Spectrometry) with creatinine normalization by Jaffe Reaction (CLIA 17D0919496); not cleared or approved by the FDA. Results reported in µg/g creatinine. Not a stand-alone diagnosis; should be interpreted in clinical context.
A derived biomarker is a value that is calculated from other directly measured biomarkers rather than being measured directly in the lab.
Key benefits of Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) testing
- Oxidative DEHP metabolite tracking
- more stable DEHP marker than MEHP
- complements MEHP for complete DEHP burden assessment
What is Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP)?
MEOHP is a secondary oxidative urinary metabolite of DEHP. As a more stable downstream metabolite, it may provide a more consistent DEHP exposure signal in some individuals than the primary metabolite MEHP. Measured via LC-MS/MS.
Why is Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) important?
MEHP and MEOHP together offer a more complete DEHP exposure assessment than either marker alone. MEOHP is considered more metabolically specific and less subject to rapid concentration fluctuation.
What insights will I get?
Your MEOHP level alongside MEHP provides a fuller view of DEHP body burden. Elevated levels may suggest ongoing contact with DEHP-containing PVC materials in food, medical, or home environments.





.avif)
.avif)

